Moxidectin: an oral treatment for human onchocerciasis

Milton, P and Hamley, JID and Walker, M and Basáñez, MG (2020) Moxidectin: an oral treatment for human onchocerciasis. Expert Review of Anti-infective Therapy. pp. 1-15. ISSN 1478-7210

[img]
Preview
Text
12882_Moxidectin_ an oral treatment for human onchocerciasis_GOLD VoR.pdf - Published Version
Available under License Creative Commons Attribution.

Download (983kB) | Preview
Official URL: https://doi.org/10.1080/14787210.2020.1792772

Abstract

Moxidectin is a milbemycin endectocide recently approved for the treatment of human onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a filarial infection endemic in Africa, Yemen, and the Amazonian focus straddling Venezuela and Brazil. Concerns over whether the predominant treatment strategy (yearly mass drug administration (MDA) of ivermectin) is sufficient to achieve elimination in all endemic foci have refocussed attention upon alternative treatments. Moxidectin’s stronger and longer microfilarial suppression compared to ivermectin in both phase II and III clinical trials indicates its potential as a novel powerful drug for onchocerciasis elimination.

Actions (Repository Editors)

View Item View Item